Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection
- Conditions
- Breast Cancer
- Interventions
- Device: Wavelia #2
- Registration Number
- NCT05757427
- Lead Sponsor
- MVG Industries SAS
- Brief Summary
The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.
Microwave imaging is an emerging imaging modality for the early detection of breast cancer. The physical basis of microwave imaging is the dielectric contrast between healthy and cancerous breast tissues at the microwave frequency spectrum.
This study is a pilot Clinical Evaluation of a microwave imaging system (Wavelia #2) for Breast Cancer Detection. The clinical data that will be collected in the context of this study is intended for the assessment of the imaging diagnostic capability and the safety of the investigational device.
- Detailed Description
This study aims to enrol approximately 103 subjects presenting to the symptomatic breast unit with a breast abnormality who consent to undergo an MBI scan using the Wavelia #2 imaging system. The study uses an adaptive design to verify and validate the technical evolutions that have been integrated in the Wavelia# 2 prototype on a small patient dataset (30 patients). Once the technical performance has been established recruitment will continue to assess the clinical performance of the MBI system compared to standard of care reference imaging. The primary objectives of the study are to assess the performance of Wavelia # 2 in the detection of malignant and benign breast lesions, the sizing of malignant lesions for which post-surgery histology data will be available and the differentiation between benign and malignant breast abnormalities by means of features extracted from the MBI images.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 73
- Informed Consent
- Female subjects with an investigator assessed discrete breast abnormality of size > 1cm
- Able and willing to comply with the requirements of this study protocol
- Negative urine pregnancy test on the day of microwave imaging procedure (if of childbearing potential)
- intact breast skin (i.e., without bleeding lesion, no evidence of inflammation and/or erythema of the breast)
- Able to comfortably lie reasonably still in a prone position for approximately 15 minutes
- Have had biopsy more than 2 weeks prior to the microwave breast investigation (if applicable)
- Have a cup size of A or whose breast is deemed too small to allow MBI assessment in the opinion of the investigator
- Are pregnant or breast-feeding
- Have had surgery on either breast within the past 12 months
- Have any active or metallic implant other than a biopsy clip
- Would be unsuitable for an MBI scan or unlikely to follow the protocol in the opinion of the Investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description All patients will have an MBI scan with Wavelia #2 in addition to standard reference imaging. Wavelia #2 Patients with an investigator assessed discrete breast abnormality of size \>1cm and who attend the symptomatic breast unit for assessment as per standard of care protocol will be considered for participation in this clinical investigation.
- Primary Outcome Measures
Name Time Method Assess the detectability rate of malignant and benign breast lesions. Duration of study - 19 months Endpoint: Percentage of malignant and benign breast lesions correctly detected with Wavelia MBI
Assess the potential for differentiation between malignant and benign breast lesions, using Wavelia MBI. Duration of study - 19 months Endpoint: Proportion of benign and malignant breast lesions correctly classified with Wavelia MBI
- Secondary Outcome Measures
Name Time Method Assess the potential for differentiation between ILC and IDC cancer types, or other cancer types (if sufficient data is available) using Wavelia MBI. Duration of study - 19 months Endpoint: Percentage of cancers correctly classified per cancer type with Wavelia MBI (e.g. ILC, IDC, other).
Assess lesion sizing for patients who have undergone surgery post MBI scan and for whom post-surgery histology data is available. Duration of study - 19 months Endpoint: Maximal linear size difference (in mm) between the MBI lesion detection and the maximal size being reported in the post-surgery histological analysis of the excised tumour.
Trial Locations
- Locations (1)
Galway University Hospital/Symptomatic Breast Unit
🇮🇪Galway, Ireland